The study drug, Nilotinib, is believed to slow down tumor growth by regulating a gene
involved in cellular growth of chordoma cells. During this research study, subjects will also
receive radiation therapy which is considered a standard treatment for advanced chordomas. It
is hoped by adding nilotinib, the benefits of radiation therapy can be enhanced without
adding significant toxicities.
The purpose of this research study is to determine the safety of nilotinib when used in
combination with radiation therapy, and the highest dose of nilotinib that can be given
safely with radiation therapy.